ShareSpot
-
Creative Responses to COVID-19
From our colleagues at TargetHIV, Creative Responses to COVID-19 highlights some of the approaches Ryan White HIV/AIDS Program grantees are taking to respond to clinic changes and provider and patient needs during this unprecedented time of COVID-19. The blog...
-
Oregon Reminders: Technology to Engage Rural Oregon Communities in HIV Care
In HIV prevention and care, rural communities are often left out of the mix. But the Oregon Health Authority, in partnership with the YTH (Youth Tech Health) Initiative at ETR, is engaging rural communities in taking charge of their HIV prevention and treatment via Oregon Reminders.
Oregon...
-
The Intersection of HIV and SUD: An Innovative Partnership to Educate and Support Two Critically Important Workforces
A network of federally funded training centers has existed since the early 1990’s to educate and build the capacity of clinicians and healthcare professionals to diagnose, treat and manage HIV and other sexually transmitted diseases (STDs), substance use disorders (SUDs), mental health disorders...
-
How one Ryan White HIV/AIDS Program (RWHAP) Part F AIDS Education & Training Center (AETC) is Addressing Accessibility and 508 Compliance
Web developers and digital content creators know that website accessibility and 508 compliance is a critical requirement. Their websites and web materials must meet all the accessibility laws and regulations. To ensure equal access to information for all, including those with disabilities....
-
Curing Hepatitis C in People with HIV in the United States: A Federal, State and Local Collaboration
Hepatitis C virus (HCV) co-infection affects roughly 25% of people with HIV in the United States (U.S.).[i] To effectively combat this epidemic, ongoing provider education has been identified as a key initiative to enhance screening, diagnosis, linkage to care, and treatment of HCV. While many...
-
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
At CROI 2019, investigators presented 48-week results from the Phase 3 international multisite ATLAS and FLAIR studies of long-acting 2-drug injectable therapy. The study regimen consisted of the integrase inhibitor cabotegravir (CAB) plus the NNRTI rilpivirine (RPV), both given every 4 weeks as...
-
PrEP: TDF/FTC vs TAF/FTC in MSM
TDF/FTC (Truvada) is the only ARV combination currently approved by the FDA for use as preexposure prophylaxis (PrEP). The multinational Phase 3 DISCOVER Study compared the efficacy and safety of TAF/FTC (Descovy) with TDF/FTC, in HIV-uninfected cisgender MSM and transgender women at high risk...
-
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), 300 mg, for use as a complete ARV regimen for initial HIV treatment of patients. The approval specifies that DTG/3TC is...
-
Immediate ART Initiation: Guide for Clinicians
Immediate antiretroviral therapy (ART) refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "treatment...
-
Short Bites: The Association between Oral Hygiene and Heart Disease
The emergence of chronic disease complications in controlled HIV disease has changed the landscape of HIV clinical care. HIV infection confers an increased cardiovascular disease risk which is thought to be due to a complex interplay of mechanistic factors. While traditional cardiovascular risk...
-
AETC IPE Programs Prepare the Next Generation of HIV Providers
Cross-posted from TargetHIV coverage of the 2018 National Ryan White Conference.
Regional AETCs across the United States are working to bring new clinicians into the HIV workforce through inter-professional education (IPE) programs. IPE trains learners in teams in clinical...
-
The LATITUDE to Stay On Track: NIH to Launch Study in People Non-Adherent to Daily Treatment
Taking effective HIV medications as prescribed offers many benefits for people with HIV—life expectancy normalizes and viral loads drop below detectable levels, preventing the risk of sexual transmission in those who achieve and maintain durable viral suppression. Unfortunately, many individuals...
-
Short Bites: The Association between Oral Disease and Type of Antiretroviral Therapy among Perinatally HIV-Infected Youth
Antiretroviral therapy (ART) has been very successful at preserving immune function and controlling opportunistic infections among individuals infected with HIV. Oral mucosal diseases associated with advanced immunosuppression, including candidiasis and hairy leukoplakia, are significantly less...
-
AETCs at the 2018 Ryan White Conference
The AETC Program was well represented at the 2018 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center exhibited an array of AETC Program developed resources and promotional items.
TitleSession IDTypePresenters/ PanelistsDate/timeHIV and... -
Sexual Assault: PEP is an Urgent Health Need
When a patient presents to your emergency department, urgent care or clinic with a chief complaint of sexual assault within the last 24 hours, the challenge is recognizing that, along with safety and criminal justice concerns, this patient has emergent health needs. One of the most urgent of...
-
Rapid ART Start
The International AIDS Society (IAS)-USA recently released its 2018 HIV treatment and prevention recommendations. The document is particularly notable for its discussion of "When to Start ART."
The IAS-USA recommends "rapid" or immediate start of ART upon diagnosis of HIV, stating that...
-
Doravirine--New NNRTI Approved by FDA
The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons that showed doravirine + 2 NRTIs resulted in similar rates of viral suppression at 48 weeks as...
-
Short Bites: HIV in the Southeast United States
Southern states today account for an estimated 44 percent of all people with an HIV diagnosis in the U.S.,[1] despite having only about one-third (37%) of the overall U.S. population. Diagnosis rates for people in the South are higher than for Americans overall. Eight of the 10 states with the...
-
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects
Integrase inhibitors have become primary treatment for most people with HIV; however, the impact of newer integrase inhibitors on pregnancy outcomes has not been well described. Researchers for the observational Tsepamo study have been examining birth outcomes in Botswanan women treated with...
-
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy
Although DTG currently is not a desirable medication for women to take pre-conception (see Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects), findings from the DolPHIN study suggest that it may be a very useful agent for women who start ART during late pregnancy....
- 1 of 5
- next ›
Search ShareSpot
Subscribe to the ShareSpot RSS FeedUser login
Suggest a Blog Topic
Is there a topic you'd like us to discuss here? Let us know!